Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vaping 1Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Stomach Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Neoplasms by Histologic Type 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × BID protein, human × Clear all
NCT05561374 2024-11-29

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Oblato, Inc.

Phase 1 Active not recruiting
16 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡